"You're Not Too Old (Yet): Do this to Reverse Mitochondrial Decline in 2026" — Nicholas Trigili, uploaded 2026-07-30, 14:47, ~9,545 views as of 2026-07-31. Metadata pulled live via yt-dlp --skip-download --print this session — not from memory. Why this is a YouTube embed, not a self-hosted file: this site's proven recipe (ffmpeg 2-pass compress to under Cloudflare's 25 MiB/file limit, self-hosted) works cleanly for the ~5–6 minute explainer clips already on this site. At 887 seconds, hitting 25 MiB would force the combined video+audio bitrate down to roughly 235 kbps — under half of what those shorter clips use — and would ship visibly degraded video. A clean embed at full source quality serves the reader better than a compressed copy. Said plainly here rather than silently substituted (the same call this site made on the SS-31 page for a 21-minute video).
0
Human Trials of This 3-Compound Stack
MOTS-c, SS-31, and NAD+ have never been tested together, at any dose, in any combination, in a registered human trial. Every serious source teaching this protocol — including the source video itself — says so.
0
Published Human Studies of Injected MOTS-c
FDA's own July 2026 compounding review, quoted below: "Published literature did not reveal studies in which compounded drug products containing MOTS-c... were used in humans." The only administered-peptide human trial in the file used a modified analog, not MOTS-c itself.
~30–1,000×
Gap: Video's NAD+ Dose vs. Clinic Practice
The video states 200–600 micrograms per injection. Independent peptide-clinic sources report typical injectable NAD+ doses of 20–200 mg. See the dedicated discrepancy section below — this is not a rounding difference.
$325–900+
Monthly Gray-Market Cost, All Three
Running all three compounds at the calculator's lower/community-tier doses below. See the Cost section for the line-by-line math and sourcing.
The stacking logic — repeated near-identically across the clinic blogs and community write-ups we found — is that each compound targets a different piece of mitochondrial function, so combining them should, in theory, cover more ground than any one alone. That is a mechanistic argument, not a tested one. Full evidence detail for SS-31 and NAD+ lives on their own dedicated pages on this site; MOTS-c gets its full treatment here since this is currently its most complete write-up on engelsplace.
MOTS-c — The Signal
AMPK Activator
A 16-amino-acid peptide encoded inside the mitochondrial 12S rRNA gene, discovered in 2015. In mice, MOTS-c translocates to the nucleus under metabolic stress and activates AMPK, the cell's energy-sensing switch — reducing diet-induced obesity and reversing age-dependent insulin resistance in the original founding study.
SS-31 (Elamipretide) — The Structure
Cardiolipin Binder
Binds cardiolipin directly, stabilizing the inner mitochondrial membrane's folded cristae. FDA-approved (as Forzinity) for one narrow pediatric indication after four separate placebo-controlled trials missed their primary endpoint. Full trial-by-trial record on this site's dedicated page.
NAD+ — The Fuel
Coenzyme Supply
A coenzyme every mitochondrion consumes to run the electron transport chain. Oral precursors (NR, NMN) reliably raise blood NAD+ in international placebo-controlled trials. Injectable/IV NAD+ floods the bloodstream faster but has thinner controlled-trial backing. Full trial record on this site's dedicated page.
The Stacking Rationale (Community, Not Tested)
3 Angles, 0 Trials
Multiple independent peptide-clinic write-ups describe the same division of labor: NAD+ supplies the fuel, SS-31 fixes the "engine" structure, MOTS-c handles metabolic signaling — a plausible-sounding argument for combining them. It is a mechanistic hypothesis assembled from three separately-studied compounds, not a tested combination. No source we found — including the clinics selling the protocol — claims otherwise.
Each individual compound has a real, searchable literature. The stack as a whole — the specific thing the video teaches — has none. That gap is the honest headline of this page.
Individual-Compound Literature
PubMed, July 2026: 247 papers on "MOTS-c" + 355 on "elamipretide" + 1,443 on "NAD+ supplementation." Not all directly relevant, but the honest raw count.
Trials of Any 2-Compound Combination
Zero found on ClinicalTrials.gov or in our PubMed sweep for MOTS-c+SS-31, MOTS-c+NAD+, or SS-31+NAD+ given together.
Trials of the Full 3-Compound Stack
Zero. This is the exact protocol taught in the video, and it has never been run as a study, on anyone, at any dose.
This is the sequence Nicholas Trigili lays out in the source video, timestamped in the description. It is reported here for what it is — one influencer's stated protocol — not validated by this site.
Days 1–14
SS-31 alone. Stated purpose: "clear oxidative stress" before adding anything else. Duration is scaled to how metabolically damaged the person is judged to be — no specific criteria for that judgment are given in the video.
Weeks 2–8
MOTS-c added. 5–10 mg per week, split across 2–3 injections (up to 5 small injections Monday–Friday), with at least 2 days off per week. SS-31 continues in parallel at a lower steady dose for the entire cycle — not just the first week.
Weeks 4–5
NAD+ added. Stated in the video as injectable "200 to 400 to potentially 600 micrograms, twice a week max" — explicitly described as not-daily. See the dedicated discrepancy section below — this figure does not match independent injectable-NAD+ dosing literature.
Coming Off
No taper — just stop. The video recommends blood work before and after the cycle, and tracking resting heart rate and HRV as the practical read-out. No specific stopping criteria or minimum/maximum cycle length is given.
Reality check: the video's own creator states plainly on-screen that he is not a doctor and that this is personal/client experience, not medical advice — and the description says peptides are "prescribed legally through licensed medical professionals" through his coaching funnel, a claim we could not independently verify (see the Incentive section below). No stopping criteria, no defined maximum cycle length, and no data on what "no taper" does after eight weeks of three concurrent, individually under-studied compounds. Track your own numbers if you try this, and read the safety section before you do.
The load-bearing table. Each row is the actual human evidence for one compound (or the closest analog tested) — not a marketing summary of it.
| # |
Study / ID |
Compound |
n |
What It Actually Found |
Outcome |
| 1 |
CB4211 · NCT03998514 — Phase 1a/1b |
MOTS-c analog (not identical peptide) |
Phase 1a healthy volunteers + Phase 1b NAFLD cohort |
Met its primary safety/tolerability endpoint. In the NAFLD arm, liver enzymes ALT and AST fell 25% and 17% vs. placebo. Development was discontinued after CohBar merged into TuHURA Biosciences — no active MOTS-c IND exists as of 2026. |
Safe, discontinued |
| 2 |
PMID 34351816 — Observational |
Endogenous MOTS-c (not injected) |
Healthy adults, acute exercise |
Confirms the body's own circulating MOTS-c rises after endurance exercise. This is evidence the peptide is real and physiologically active — it is not evidence that injecting synthetic MOTS-c does anything, and should never be cited as such. |
Endogenous only |
| 3 |
TAZPOWER · PMID 38602181 |
SS-31 (elamipretide) |
12 |
Missed its primary endpoint (6-min walk, fatigue score) vs. placebo. Became the basis for FDA approval anyway, on secondary strength data. Full detail on the SS-31 page. |
Missed primary, FDA-approved anyway |
| 4 |
PMID 31572171 — Pilot PK study |
Injectable NAD+ (IV) |
Small pilot |
Tracked plasma/urine NAD+ metabolome during a 6-hour, 750 mg IV infusion. Confirms the molecule floods into the system — not a claim about clinical benefit. 750 mg is roughly 1,250–3,750× the per-dose amount stated in the source video. |
PK confirmed only |
| 5 |
PMID 41704678 — Retrospective pilot |
Injectable NAD+ (IV) vs. oral NR |
Real-world clinic cohort |
2026 retrospective tolerability comparison between IV NAD+ and oral NR in a real-world clinic setting. Tolerability-focused, not a controlled efficacy trial. |
Retrospective |
| 6 |
— |
The 3-compound stack itself |
0 |
No registered or published human trial of MOTS-c + SS-31 + NAD+ given together, in any sequence, at any dose, exists as of July 2026. Bounded to our PubMed + ClinicalTrials.gov + non-PubMed sweep this session. |
Never tested |
Reality check (honest reading): this is not "no evidence exists" — it's "the parts are studied, the combination isn't." MOTS-c's own literature is thinner than the other two: the FDA's own July 2026 compounding review states plainly, "Published literature did not reveal studies in which compounded drug products containing MOTS-c or MOTS-c acetate were used in humans" — quoted verbatim below in the Regulatory section. The one real human peptide-injection trial in this file (CB4211) tested a modified analog for a different purpose (NASH/obesity), not the compound sold as "MOTS-c" today, and that program has no active sponsor left. That is a funding-and-pipeline finding, not proof the peptide fails — say which one you mean.
This is the single most important thing to check before acting on this video. The stated dose does not match what independent sources describe as typical injectable NAD+ dosing — by a wide margin.
What was said vs. what the independent sources describe
200–600 mcg
Stated in the video
= 0.2–0.6 mg per injection, "twice a week max." This is the number Nicholas Trigili states on-screen at 8:09 in the source video.
20–200 mg
Independent Clinic Sources (SC)
Multiple independent peptide-clinic and pharmacy write-ups describe subcutaneous NAD+ protocols starting around 20 mg and titrating to 50–200 mg per injection, 2–3 times weekly during a loading phase.
750 mg
Published IV Trial Dose
The one published human pharmacokinetic pilot study of IV NAD+ (PMID 31572171) used a single 750 mg, 6-hour infusion — a different route, same order-of-magnitude gap.
The math: 0.6 mg (the video's upper figure) into 20 mg (the clinic-literature lower bound) is roughly 33 times too low. 0.2 mg (the video's lower figure) into 200 mg (the clinic-literature upper bound) is roughly 1,000 times too low. Against the 750 mg IV trial dose, the gap widens to nearly 3,750 times — though that comparison mixes routes (IV vs. the video's implied SC/IM) and is included for scale, not as a like-for-like ratio.
We are not telling you which number is "right." We could not identify a controlled human trial establishing an optimal injectable NAD+ dose for any wellness use — the clinic-reported range itself comes from practice patterns, not RCTs, and is T4-tier evidence (see footer). What we can say plainly: the video's figure sits far outside the range independent sources describe, and using a home dose-calculator built around the clinic range (below) with the video's stated micrograms would draw a volume too small to reliably measure on a standard insulin syringe. If you are being dosed by someone else under this protocol, ask them directly what concentration and volume you are actually receiving, in writing, before you inject anything.
Real current gray-market prices for each compound, at the lower/community-tier doses the calculator below uses. These are unregulated research-chemical vendor prices, not clinic service fees.
Unregulated / T5
MOTS-c
$100–480
per month · $5–12/mg, ~20–40 mg/month at the source video's 5–10 mg/week
No prescription, no FDA sterility/potency oversight
Unregulated / T5
SS-31 (Continuation Dose)
$225–390
per month · $75–130 per 10 mg vial, ~1 mg/day steady dose
Full FDA-approved-vs-gray-market pricing on the dedicated
SS-31 page
Two Different Numbers
NAD+ Raw Powder
<$1 vs $28–288
per month · at the video's mcg dose vs. the clinic-literature mg dose (see discrepancy card above)
$0.07–0.24/mg raw material — the 1,000x price gap mirrors the 1,000x dose gap
Clinic NAD+ IV/Injection Service
$200–2,000
per session, full-service clinic (not raw material)
The price gap tracks clinic margin, not proof — see the dedicated NAD+ page
Most Human RCTs
Exercise (Vigorous, 75–149 min/wk)
$0
zero direct cost
HR 0.81 for all-cause mortality — about 19% lower, not the round-number "third" sometimes quoted. 116,221 US adults, 30-year follow-up. Observational, not randomized — still the best-evidenced mitochondrial-biogenesis intervention available.
💰 Follow the Money — Precisely Stated
MOTS-c's missing trials are a funding story, not a failure story. The one company that ran a real human trial on a MOTS-c analog (CohBar, CB4211, NCT03998514) merged into TuHURA Biosciences after that program stalled — there is no active sponsor left to fund a definitive trial of native MOTS-c itself. A 16-amino-acid peptide with no patent protection on the "MOTS-c" sequence and no active drug-development program is exactly the kind of compound this site's doctrine expects to see under-tested — not because it failed, but because nobody currently stands to profit from running the trial.
The vendor side is the opposite problem. Dozens of "research use only" vendors sell MOTS-c, SS-31, and NAD+ at $5–130 per unit with no FDA sterility or potency oversight. The FDA's April 2026 enforcement wave sent warning letters to online peptide sellers for marketing research-labeled products with disease/wellness claims — we did not find a warning letter naming MOTS-c, SS-31, or NAD+ specifically, but we did pull one directly on-point letter (Gram Peptides, March 31, 2026) targeting the same "research use only" injectable-peptide-plus-bacteriostatic-water sales pattern these three compounds are sold under. Its own language, quoted verbatim: "Despite statements on your product labeling marketing your products for 'Research Use Only,' and 'not intended for human consumption, medical use, or veterinary use,' evidence obtained from your website establishes that your products are intended to be drugs for human use."
The coaching/content side has its own incentive. The source video's own description drives viewers to a paid 1:1 coaching application and a free opt-in "mitochondrial stack blueprint" — disclosed plainly in the Incentive section below.
Pick a protocol tier for each compound, tell the calculator what you actually mixed, and it gives you the exact syringe mark. MOTS-c is dosed weekly and split across several injections — pick the tier and it shows you the per-injection amount and the weekly total together, the same way this site's TB-500 calculator handles weekly-total peptides. The NAD+ calculator includes the video's own stated dose as one selectable option, deliberately left in so you can see for yourself what it does to the syringe math (watch what happens at "Video-Stated Dose" — the sub-2-unit warning is the calculator's own honesty check, not a bug).
MOTS-c
SS-31 (Continuation Dose)
NAD+
All three compounds carry different, non-interchangeable regulatory statuses — worth knowing which one you're actually relying on.
FDA — MOTS-c, July 23–24, 2026 PCAC Review
Recommended Against 503A Bulks Listing
The FDA's own briefing document, quoted verbatim:
"Published literature did not reveal studies in which compounded drug products containing MOTS-c or MOTS-c acetate were used in humans." And:
"There is a lack of clinical and nonclinical safety information on the use of MOTS-c... potential safety risks associated with the use of MOTS-c in humans are unknown." The Category 2 (significant-safety-concern) listing that had blocked compounding outright was lifted April 15, 2026 — but this July 2026 review proposes MOTS-c NOT be added to the 503A Bulks List that would formally authorize compounding pharmacies to use it, citing lack of human safety/effectiveness data and unresolved immunogenicity risk from injection-route aggregation.
→ FDA PCAC Briefing Document (primary document, verified this session)
USADA / WADA — MOTS-c
Prohibited in Sport
Listed under WADA Prohibited List Section S4.4 (AMPK activators). USADA's own guidance:
"Currently it is unknown under what conditions (if any) it is safe to use MOTS-c because there are no completed clinical trials," and documents reported side effects including heart palpitations, injection-site irritation, insomnia, and fever from user reports — with no long-term safety data and no Therapeutic Use Exemption pathway available.
→ USADA, "What Is the MOTS-c Peptide?"
FDA — SS-31 (Elamipretide)
Approved (Narrow) as Forzinity
FDA-approved under accelerated approval, September 2025, for Barth syndrome muscle strength only (patients ≥30 kg) — granted after 8 internal FDA reviewers recommended against approval. Full detail, including the FDA label's own hard safety stops, on this site's
dedicated SS-31 page.
FDA — NAD+
No Approved Injectable Product; No Official Dose
No FDA-approved injectable NAD+ drug or official "anti-aging" dose exists — full regulatory and market detail, including the 2022 attempt to restrict oral NMN, on this site's
dedicated NAD+ page. Injectable/IV NAD+ sold today is an unregulated compounded/gray-market product.
Named credentialed voices who've actually addressed this stack or its components, set against the controlled evidence above — and one influencer we found teaching the same protocol whose credential does not hold up on verification.
📚 What the Controlled Evidence Shows
Each compound has real, independently-replicated mechanistic data. None of the three has been tested in combination, and MOTS-c specifically has zero published human studies of the compounded/injected form — the FDA's own words, quoted above.
SS-31's controlled human trial record is 0-for-4 on primary endpoints across four diseases (full detail on its own page); NAD+ precursors have real positive human RCTs orally, thinner evidence by injection.
The one real human trial touching a MOTS-c-like molecule (CB4211) tested a modified analog for NASH/obesity, met its safety endpoint, and the program has since lost its sponsor.
🩺 What Practitioners Report
Dr. Iman Bar, MD — practicing physician since 1990, founder of the BARx concierge men's-health clinic (Newport Beach, CA, est. 2020). Credential independently verified via
Doximity and
WebMD's physician directory. Her clinic's own protocol write-up combines SS-31 (2–5 mg/day) with MOTS-c (5 mg, 2–3×/week) — dosing guidance, not a published case series with outcome numbers, which we state plainly as a limitation.
Dr. Ashley Froese, DO — primary care, Arizona, this site's banked expert roster. Own video,
"The Truths about Mots-C Nobody is Talking About" (2026-06-07, 9:01, ~267,000 views as of 2026-07-31, verified live via yt-dlp). Frames MOTS-c as promising but under-tested.
Discloses a commercial interest: links her own paid peptide course and a cold-plunge affiliate link in the description.
Dr. Kristi Sawicki, PhD (molecular & cellular oncology, George Washington University; postdoctoral fellowship in epigenetics, Columbia) —
not a licensed physician; runs a women's peptide/longevity coaching community. Her video,
"The Mitochondria Longevity Stack: MOTS-c, SS-31, NAD+ Explained" (2026-04-26, 25:41, ~2,977 views as of 2026-07-31, verified live) is the closest thing we found to a dedicated explainer of this exact 3-compound stack. Credentials genuine per verification; prescribing authority is not implied by a PhD, and none was claimed.
Nicholas Trigili (the source video) — explicitly states on-screen and in writing that he is not a doctor. Background: former IFBB Pro bodybuilder, founder of TruGenetics, ~20 years coaching 10,000+ clients per his own site. His video description states peptides referenced are "prescribed legally through licensed medical professionals" through his coaching funnel — we could not independently verify what that oversight consists of from public sources.
Who We Dropped, and Why
Our yt-dlp search for this stack surfaced a video with 57,234 views from "Dr. Trevor Bachmeyer" discussing MOTS-c, NAD+, and SS-31 together. We checked his credential before citing him, per this site's verification rule. The California Board of Chiropractic Examiners' own July 2020 disciplinary-actions document (retrieved via web.archive.org after the live FDA-style board URL 404'd — full retrieval-ladder note in the footer) lists: "Bachmeyer, Trevor, Alamo, CA — License No. DC 29377 — Action: Revoked — Effective Date: 7/8/2020." That is the one fact we can assert with confidence from the primary document; the extracted text bundles a longer violations list across two revoked licensees without clearly separating which items apply to which name, so we are not asserting the specific violations beyond the confirmed revocation itself. He continues to present himself online as "Doctor" and "the World's #1 Health Authority" without a current chiropractic license. We are not citing him as a source anywhere on this page — high view count is not credibility, and this site's own rule is to leave someone off the page entirely if their credential doesn't verify, no matter how many people are watching.
The Incentive Behind the Source Video
Stated plainly: the video does not push a specific product, brand, or discount code on-screen. Its description links to (1) a "1:1 coaching" application with Trigili's team, and (2) a free email opt-in for "the full mitochondrial stack blueprint." Both are real, disclosed calls to action — neither is a hidden sponsorship, and we found no undisclosed product placement. Readers should know a coaching funnel sits behind a video that frames a specific, buyable protocol as the answer to feeling "exhausted."
Each compound has its own risk profile — none of them have been safety-tested in combination, which is a different and larger unknown than any one compound's individual risk.
MOTS-c — Immunogenicity Risk (FDA's Own Concern)
Unresolved
FDA's language, quoted verbatim: "Compounded drugs containing MOTS-c (free base) may pose significant risk for immunogenicity when administered by injection routes due to potential of aggregate formation as well as potential peptide-related impurities." USADA separately documents user-reported heart palpitations, injection-site irritation, insomnia, and fever — with no long-term human safety data behind any of it.
→ FDA PCAC Briefing Document, 2026 (primary document)
SS-31 — Real, On-Label Hypersensitivity Risk
Documented
The FDA-approved Forzinity label documents real hypersensitivity reactions, including serious ones requiring emergency care, occurring "within minutes to months" of starting. Full FDA label quotes and the 100%-vs-67% injection-site-reaction data from the pivotal trial are on the dedicated SS-31 page.
NAD+ — Rate-Dependent Side Effects
Dose/Rate-Dependent
Flushing, nausea, headache, and dizziness are the most commonly reported effects of injectable/IV NAD+, and independent sources describe them as dose- and infusion-rate-dependent — supporting titrating up slowly rather than starting at a high dose. This is a separate issue from the dose-discrepancy question above.
Sourcing / Purity Risk — All Three
HIGH (gray-market)
None of the three compounds, at the doses this protocol uses, comes from a pharmacy with FDA sterility or potency oversight. "Research use only" vials carry no guarantee the labeled dose matches the actual contents — a real, separate risk layered on top of the compounds' own individual profiles.
→ Market-reporting pattern; see the FDA Gram Peptides warning letter quoted above
⛔ The unstudied combination is itself the biggest unknown. No trial has evaluated what happens when a peptide with unresolved immunogenicity concerns (MOTS-c) is layered with a compound that has documented hypersensitivity reactions on its own approved label (SS-31), plus a coenzyme whose injectable dose in this specific protocol may be off by up to three orders of magnitude from independent clinical practice (NAD+) — run concurrently, then stopped abruptly with no taper. That is not a claim any specific harm will occur; it is a claim that nobody has looked, and the video does not claim otherwise either.
✓ What seems reassuring (provisionally): across all three individual-compound literatures, no organ-toxicity or overdose signal was found at the doses these community protocols use — the dominant reported effects are injection-site reactions, mild flushing/nausea, and (for MOTS-c) unresolved immunogenicity risk rather than acute danger. That is meaningfully different from "safe" — it means the individual compounds look tolerable at low community doses in the reports we found, not that the combination has been checked.
An honest read of the Mitochondrial Triple Stack in 2026
What it is: a sequenced protocol combining three real, separately-studied mitochondrial compounds — MOTS-c (a signaling peptide), SS-31 (a structural peptide with one narrow FDA approval), and NAD+ (a coenzyme, injectable form unregulated) — popularized by a fitness/biohacking coach's July 2026 video and echoed by several telehealth peptide clinics.
Who's using it: Longevity-focused biohackers and telehealth wellness patients working with peptide clinics, plus people following influencer-taught protocols directly. Some clinicians (Dr. Iman Bar, MD, among them) publish similar combination-dosing guidance; none published patient-outcome data for the combination specifically.
What the law says: the three compounds sit in three different legal categories. SS-31 is a legitimate FDA-approved drug for one narrow indication; "research use only" SS-31 for anything else is not that approved product. MOTS-c was just recommended AGAINST formal compounding authorization by FDA's own advisory review, on top of its earlier Category 2 safety flag. Injectable NAD+ has no FDA-approved product or official dose at all. None of the three is legal to buy pre-mixed for general wellness use without a prescription from the compounding pathway that exists for it.
What the research shows: real, separate, honest evidence for each compound individually — and zero human trials of any combination, let alone all three together. MOTS-c specifically has no published human studies of the injected/compounded form at all, per FDA's own July 2026 review. The video's stated NAD+ dose (200–600 micrograms) does not match independent clinic-reported dosing (20–200 mg) by roughly one to three orders of magnitude — a discrepancy this page could not resolve in the video's favor and is not our place to resolve for you.
- This is three individually-studied compounds combined into an untested protocol — not a tested stack. Say that distinction out loud before deciding anything.
- MOTS-c has zero published human studies of the injected form, confirmed by FDA's own words. Its evidence is entirely animal/mechanistic plus one discontinued analog trial.
- The NAD+ dose discrepancy is real and large — confirm the actual concentration and volume with whoever is dosing you before you inject anything based on this protocol.
- SS-31 and NAD+ each have their own dedicated, deeper evidence pages on this site — read those before deciding on either compound specifically.
- An unlicensed influencer (revoked chiropractic license) is one of the loudest voices teaching a version of this exact stack online — verify who you're actually listening to.
- Not medical advice. Talk to a licensed physician — and ask specifically about combination safety, since no trial has looked at that question for any of these three compounds together.